< Back EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of zorevunersen (STK-001) in Patients with Dravet Syndrome Study Details Internal Title: Gene Therapy STK-001-DS-301 EMPEROR PCH IRB Number: IRB-25-213 Clinical Trials Government Identifier: 06872125 Study Type: Clinical Trial Enrollment Status: Open Phase: III Coordinator Contact: NIGEL NEGMContact Email: nnegm@phoenixchildrens.com Principal Investigator Angus A. Wilfong, MD Division Chief, Neurology; Dr. Jerry Cox Endowed Chair in Neurology Contact Us × Sent From: Send To: Subject: Message: